Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder and mutations in superoxide dismutase 1 (SOD1) account for 20% of familial ALS cases. The aetiology of ALS remains unclear, but protein misfolding, endoplasmic reticulum (ER) stress and neuronal apoptosis are implicated. We previously established that protein disulphide isomerase (PDIA1) is protective against ER stress and apoptosis in neuronal cells expressing mutant SOD1, and recently mutations in PDIA1 and related PDI family member endoplasmic reticulum protein 57 (ERp57/PDIA3), were associated with ALS. Here, we examined whether ERp57 is also protective against mutant SOD1 or whether distinct specificity exists amongst individual PDI family members. Neuronal cells co-expressing SOD1 and ERp57 were examined for inclusion formation, ER stress, ubiquitin proteasome system (UPS) dysfunction and apoptosis. Over-expression of ERp57 inhibited inclusion formation, ER stress, UPS dysfunction and apoptosis, whereas silencing of ERp57 expression enhanced mutant SOD1 inclusion formation, ER stress and toxicity, indicating a protective role for ERp57 against SOD1 misfolding. ERp57 also inhibited the formation of mutant SOD1 inclusions and apoptosis in primary cortical neurons, thus confirming results obtained from cell lines. ERp57 partially colocalized with TAR DNA-binding protein-43 (TDP-43)-positive inclusions in spinal cords from sporadic ALS patients, thus linking ERp57 to protein misfolding in human sporadic disease. Our results therefore imply that ERp57 has a protective role against pathological events induced by mutant SOD1 and they link ERp57 to the misfolding of TDP-43. This study therefore has implications for the design of novel therapeutics based on the activities of the PDI family of proteins.
Introduction
Amyotrophic lateral sclerosis (ALS) is an aggressive, adult-onset neurodegenerative disorder characterized by the degeneration of both upper motor neurons in the primary motor cortex and lower motor neurons in the brainstem and spinal cord (1, 2) . Although 90% of cases lack an obvious genetic component (sporadic ALS, sALS), 10% of cases are inherited, termed familial ALS (fALS) (3) . Mutations in the superoxide dismutase1 (SOD1) gene account for approximately 20% of fALS and 2% of sALS cases and SOD1 remains the most widely studied gene associated with ALS (4) . Over 170 different ALS-linked SOD1 mutations have now been identified, throughout all five exons of the SOD1 gene (5) . Sporadic and SOD1-linked ALS share many pathological hallmarks, signifying that an understanding of the SOD1-linked forms of disease should have broader application to other ALS cases. A major hallmark of mutant SOD1-linked ALS is the formation of SOD1-immunopositive inclusions found within motor neurons (6) . Several proteostasis mechanisms are known to be disrupted in ALS, including protein degradation, protein misfolding and accumulation, cellular trafficking defects and endoplasmic reticulum (ER) stress (7, 8) .
ALS is a protein misfolding disorder and impaired ubiquitin-proteasome system (UPS)-dependent protein degradation is associated with ALS pathogenesis. ALS-associated misfolded proteins SOD1 and TAR DNA-binding protein-43 (TDP-43) are resistant to degradation via the UPS, and they consequently aggregate to form intracellular inclusions observed in fALS mice models and post-mortem spinal cords of ALS patients (9) (10) (11) (12) . TDP-43 is ubiquitinated in the brains of $50% of patients with frontotemporal lobar degeneration (FTLD-TDP) and in spinal cords of ALS patients (10) . Moreover, TDP-43 is misfolded, hyper-phosphorylated, fragmented and mislocalized from the nucleus to the cytoplasm, in almost all ALS patients (97%) (13) . The formation of abnormal disulphide bonds is implicated in the aggregation of both TDP-43 and SOD1 (14) (15) (16) . Hence, chaperones that prevent protein misfolding and reshuffle aberrantly formed disulphide bonds may be protective in ALS.
The protein disulphide isomerase (PDI) family of chaperones are induced during ER stress, which triggers the unfolded protein response (UPR). ER stress is induced when the load of misfolded proteins within the ER increases, leading to the activation of ER stress sensors: protein-kinase-like endoplasmic reticulum kinase (PERK), inositol requiring kinase-1 (IRE-1) and transcription factor 6 (ATF6) (17) . Activation of IRE-1 results in the splicing of transcription factor X-box-binding protein-1 (XBP-1) messenger RNA, to remove a stop codon and produce a functional transcriptional factor. If prolonged, the UPR leads to apoptosis, and the activation of nuclear CCAAT-enhancerbinding protein homologous protein (CHOP), which regulates the cellular transition from pro-survival to pro-apoptotic signalling (18, 19) . Activation of the UPR results in a decrease in general protein translation and induction of ER chaperones, including PDI/PDIA1 and endoplasmic reticulum protein 57 (ERp57/PDIA3). Both PDIA1 and ERp57 mediate the formation and rearrangement of protein disulphide bonds (20) . ER stress and the UPR are now widely implicated in both sporadic and familial forms of ALS (21) (22) (23) (24) (25) and ALS-associated mutations in SOD1 induce the UPR in cell culture (26) . ER stress is also observed in the early stages of disease in transgenic SOD1 G93A mice in the motor neurons that degenerate first (21, 27) and in cells bearing the chromosome 9 open reading frame 72 (C9ORF72) repeat expansion mutation, which is linked to a large proportion of cases of fALS (28) . Moreover, ER stress is present in human sporadic lumbar spinal cords (21) , indicating an important role in disease pathogenesis.
More than 21 PDI family members have now been identified. They share a cysteine-x-x-cysteine (CXXC) active site motif within a catalytic thioredoxin-like domain, which is responsible for disulphide isomerase activity (29) . PDI family members, which include PDIA1, ERp57, ERp72 (PDIA4) and PDIA2 (PDIp), vary primarily in substrate specificity and enzymatic activity due to differing redox potentials (30) . PDIA1 is the prototype of the thioredoxin family, which consists of four domains; the catalytically active a and a 0 domains, the substrate binding b and b 0 domains and an acidic c terminus (31) . ERp57 is the family member most similar to PDIA1 in terms of sequence homology and it shares the same domain architecture as PDIA1 (a-bb 0 -a 0 -c) (29, 32) . ERp57 is an abundant ER protein that associates non-covalently with the chaperones calnexin and calreticulin (33) in the folding of glycoproteins, but it is also linked to nonglycosylated proteins (34) . Evidence exists for functional overlap between PDIA1 and ERp57, suggesting at least partial redundancy and possible compensation between different PDI family members (35) . Recent studies have demonstrated an important role for the PDI family of proteins in ER homeostasis and in ALS pathology. PDIA1 associates with SOD1
G93A inclusions in neuronal cells in culture (26, 36) . PDIA1 also co-localizes and interacts with TDP-43 and fused in sarcoma (FUS) inclusions in tissues of ALS patients (37, 38) and with mutant vesicle-associated membrane protein-associated protein B and C (VAPB), which is linked to a rare familial form of ALS in Drosophila models (39) . Furthermore, over-expression of PDIA1 prevents the formation of mutant SOD1 inclusions in cell culture, whereas silencing PDIA1 expression enhances inclusion formation (26) . More recently, intronic variants of the gene encoding PDIA1 were reported to be risk factors for ALS (40) , and 16 missense mutations; 9 in PDIA1 and 6 in the PDIA3 gene, encoding ERp57, were identified in ALS patients (41, 42) . Novel roles for PDI family members in neurons were also described, including mediating neurite outgrowth and synaptic function (43) . Accumulating evidence highlights an important role for ERp57 in neurodegenerative diseases. ERp57 is the most upregulated protein in patients with prion disease (44) . It also physically associates with b-amyloid peptides in the cerebrospinal fluid of Alzheimer's disease patients, and it inhibits b-amyloid aggregation (45) . ERp57 is up-regulated in cellular models of Parkinson's disease (46, 47) and it also contributes to peripheral nerve regeneration in ERp57 transgenic mice models (48) , supporting a role for ERp57 in neuronal connectivity. Recently, knockdown of ERp57 in mice was shown to induce motor dysfunction and neuromuscular synapse loss (43) . ERp57 was previously found to be up-regulated in spinal cords of transgenic SOD1 G93A mice and of sALS patients, and in peripheral mononuclear cells from ALS patients, similar to PDIA1 (21), indicating that it may have a protective role in ALS. ERp57 has also been implicated as a possible biomarker to monitor disease progression (49) . However, whilst PDIA1 is protective in cells expressing mutant SOD1, it is unknown whether ERp57, or any other PDI family members, are also protective in cells expressing mutant ALS proteins. Since PDI family members share sequence similarities with the archetype PDIA1, it is possible that ERp57, its closest homologue, may have interchangeable functions with PDIA1 in relation to ALS. Alternatively, it is possible that PDI family members display unique specificity in their action against individual misfolded proteins. In this study, we examined whether ERp57 is protective in neuronal cells expressing mutant SOD1, similar to PDI. We demonstrate here that ERp57 can abrogate inclusion formation, ER stress, induction of apoptosis and UPS dysfunction in cells expressing mutant SOD1, revealing that ERp57 is protective against protein misfolding induced by mutant SOD1. This study therefore offers novel insights into the broad therapeutic role of the PDI family members in ALS.
Results

ERp57 inhibits mutant SOD1 aggregation and inclusion formation in neuronal cell lines
Firstly, ERp57 tagged with V5 was expressed in motor neuronlike NSC-34 cells with SOD1-EGFP (enhanced green fluorescent proteins). Immunoblotting was performed to confirm that similar levels of protein were expressed in the different cell populations and that these proteins were of the expected size (Fig. 1A) . ERp57 was detected in transfected cell lysates using an anti V5-tag antibody (60 kDa) and b-actin (43 kDa) was used as a loading control. Wild-type SOD1 and ALS-linked mutant SOD1 proteins (SOD1-A4V and SOD1-G85R) were detected at the expected size of 55 kDa, using an anti-GFP antibody. Quantitation of immunoblots by densitometry confirmed that over-expression of ERp57 did not significantly alter SOD1 protein levels when normalized to b-actin (Fig. 1B) .
Ubiquitinated SOD1-aggregates are a common neuropathological feature of mutant SOD1 disease models and SOD1-linked ALS (47) . To examine the effect of ERp57 against mutant SOD1 misfolding and aggregation, the insoluble cellular fractions from motor neuron-like NSC-34 cells co-expressing SOD1-EGFP with ERp57-V5 were examined. Immunoblotting of the 1% SDSinsoluble protein fraction, solubilized using urea using anti-SOD1 and anti-ubiquitin antibodies, was performed under nonreducing conditions at 72 h post-transfection. In cells expressing mutant SOD1
A4V or SOD1
G85R
, SDS-insoluble SOD1 and highmolecular weight (HMW) ubiquitinated protein conjugates were present as described previously (26) . However, over-expression of ERp57 with SOD1 A4V or SOD1 G85R resulted in a decrease in the levels of SDS-insoluble mutant SOD1 protein conjugates, compared to mutant SOD1 alone (Fig. 1C) . Furthermore, ERp57 significantly decreased the levels of ubiquitinated protein conjugates, compared to mutant SOD1 alone (*P < 0.05, Fig. 1D ). Hence, these data suggest that over-expression of ERp57 attenuated the formation of HMW mutant SOD1 aggregates. In cell culture, mutant SOD1 misfolds and forms cytoplasmic inclusions, which are defined here as large protein aggregates visible under a light microscope (26, 50) . Hence, it was next examined whether ERp57 could prevent the formation of mutant SOD1 inclusions in neuronal cell lines. NSC-34 cell lines were transfected with constructs encoding SOD1-EGFP and ERp57-V5. At 72 h post-transfection, cells were imaged using confocal fluorescence microscopy and the percentage of transfected cells (visualized by the presence of EGFP fluorescence) bearing mutant SOD1 inclusions was quantified (Fig. 1E) . Cells expressing EGFP alone or wild-type SOD1 formed very few inclusions (<1%), as expected. Similar to previous observations (26) , this contrasted with 17% of cells co-expressing mutant SOD1 A4V with empty vector (pcDNA3.1) that formed inclusions. However, when ERp57 was co-expressed with mutant SOD1
A4V
, this proportion was significantly decreased to 10% of cells (**P < 0.01). Similarly, 16% of cells expressing mutant SOD1 G85R formed inclusions, but when ERp57 was co-expressed with mutant SOD1
G85R
, this proportion was significantly decreased to 9% of cells (**P < 0.01, Fig. 1F ). Hence these data suggest that over-expression of ERp57 is protective against the formation of mutant SOD1 inclusions.
Knockdown of ERp57 enhances mutant SOD1 inclusion formation in neuronal cell lines
Since ERp57 over-expression inhibits mutant SOD1 inclusion formation, we hypothesized that knockdown of ERp57 would have the opposite effect. We used small interfering RNA (siRNA) to specifically deplete ERp57 from NSC-34 cells expressing wildtype SOD1, or mutants SOD1  A4V or SOD1  G85R . NSC-34 cell lines were transfected with SOD1-EGFP and siRNA targeting ERp57 or non-targeting control siRNA. Immunoblotting was performed at 72 h post-transfection to examine the expression levels of ERp57. Quantitation of immunoblots by densitometry demonstrated that the levels of ERp57 were significantly decreased in wild-type SOD1, mutant SOD1 A4V and mutant SOD1 G85R expressing cells treated with siRNA targeting ERp57 (Si ERp57), compared to those treated with control, non-targeting siRNA (Si CON) when normalized to b-actin, therefore confirming knockdown of ERp57 (*P < 0.05 mutant SOD1, and **P < 0.01 wild-type SOD1, Fig. 2B ). SOD1-EGFP expression was consistent between Si CON and Si ERp57 transfected cells, determined by immunoblotting using anti-GFP antibodies, demonstrating that treatment with siRNA did not perturb the levels of SOD1 expression.
Immunoblotting of the 1% SDS-insoluble protein fraction under non-reducing conditions, solubilized using urea and probed using an anti-ubiquitin antibody, was also performed at 72 h post-transfection (Fig. 2C ). In cells expressing mutant SOD1
A4V
or SOD1 G85R HMW ubiquitinated protein conjugates were present, as described previously (26) . Moreover, silencing of ERp57 resulted in a significant increase in the levels of ubiquitinated protein conjugates, compared to mutant SOD1 cotransfected with non-targeting control siRNA-Si CON (*P < 0.05 SOD1 A4V and **P < 0.01 SOD1
G85R
, Fig. 2D ). Hence, these data suggest that silencing ERp57 increased the formation of HMW ubiquitinated species.
Next, at 72 h post-transfection, cells were imaged using confocal fluorescence microscopy and the percentage of transfected cells (visualized by the presence of EGFP fluorescence) bearing mutant SOD1 inclusions was quantified (Fig. 2E) . The percentage of cells forming mutant SOD1 A4V (24%) or mutant SOD1 G85R (20%)
inclusions was significantly increased when SOD1 was cotransfected with Si ERp57, compared to when SOD1 was cotransfected with Si CON (SOD1
A4V
, 41%, ***P < 0.001 and SOD1
G85R
, 32%, **P < 0.01, Fig. 2F ). However, the wild-type SOD1 expressing cells did not form inclusions with or without ERp57 siRNA transfection in NSC-34 cells, as expected.
ERp57 inhibits the formation of mutant SOD1 inclusions in primary neurons
To validate the results obtained using cell lines (Fig. 1D) , mouse cortical neurons at embryonic day 16-18 were co-transfected with SOD1-EGFP and ERp57-V5 constructs as above (Fig. 3A) . Few inclusions formed in EGFP alone or wild-type SOD1 (10%) expressing cells, as expected. In contrast, similar to previous observations (51) , 70% (****P < 0.0001) of primary neurons co-expressing mutant SOD1
A4V with empty vector (pcDNA3.1) formed inclusions. However, this proportion was significantly reduced to 24% (****P < 0.0001) of cells when ERp57 was co-expressed with mutant SOD1 A4V (Fig. 3B) . Hence, ERp57 is protective against the formation of mutant SOD1 inclusions in primary neurons, thus confirming the results obtained in cell lines.
ERp57 inhibits ER stress induced by mutant SOD1 in neuronal cell lines
Since ERp57 is a chaperone, which shares structural similarities with PDIA1, the effect of ERp57 against induction of ER stress in cells expressing mutant SOD1 was next examined. Using ble HMW ubiquitinated proteins SOD1 A4V and SOD1 G85R populations were lower when ERp57 was co-expressed with mutant SOD1 compared to mutant SOD1 expressed immunocytochemistry, two markers of ER stress were used to specifically examine and quantify individual transfected cells, as described previously (26, 52) . Nuclear immunoreactivity for XBP-1 was used to detect activation of the IRE-1 pathway, indicating the early phase of UPR, and nuclear immunoreactivity to CHOP was used to examine activation of the PERK and ATF-6 pathways, during pro-apoptotic phases of UPR. NSC-34 cells were co-transfected with SOD1-EGFP and ERp57-V5 constructs for 72 h. Firstly, immunocytochemistry using anti-XBP-1 antibodies was performed and cells with nuclear immunoreactivity to XBP-1 were quantified using confocal microscopy ( Fig. 4A) with ERp57 resulted in significantly fewer cells with nuclear XBP-1 immunoreactivity (28%, **P < 0.01). Similarly, when ERp57 was co-expressed with mutant SOD1
G85R
, the proportion of cells with nuclear XBP-1 immunoreactivity was significantly decreased (10%, ***P < 0.001). Hence these data imply that ERp57 is protective against mutant SOD1-induced ER stress.
To confirm these findings, we also used siRNA to specifically deplete ERp57 from NSC-34 cells expressing wild-type SOD1, SOD1 A4V or SOD1 G85R . NSC-34 cell lines were transfected with SOD1-EGFP and either Si ERp57 or Si CON for 72 h. Immunocytochemistry using anti-XBP-1 antibodies was performed and cells with nuclear immunoreactivity to XBP-1 were quantified using fluorescence microscopy ( Fig. 4C ). The percentage of cells displaying nuclear immunoreactivity to XBP-1 expressing SOD1 A4V (45%) or SOD1 G85R (44%) was significantly increased in Si ERp57-treated cells (Fig. 4D ), compared to control Si CON-treated cells (58%, **P < 0.01, for SOD1 A4V or 58%, **P < 0.01, for SOD1
). In contrast, significantly fewer cells with nuclear immunoreactivity to XBP-1 were present in wildtype SOD1 populations with (16%) or without (14%) ERp57 siRNA treatment.
Next, immunocytochemistry of cells expressing SOD1 with ERp57 was performed using anti-CHOP antibodies at 72 h posttransfection. Quantification using confocal microscopy ( Fig. 5A ) revealed that similar to XBP-1, only 2% of untransfected cells (Un) or cells expressing EGFP, and only 4% of cells expressing wild-type SOD1, displayed nuclear CHOP immunoreactivity. As expected, a much greater proportion of cells co-expressing SOD1 A4V with empty vector displayed nuclear immunoreactivity to CHOP (58%, Fig. 5B ), indicating activation of pro-apoptotic UPR. However, this proportion was significantly decreased by co-expression with ERp57 (42%, **P < 0.01). Similarly, a greater proportion of cells expressing mutant SOD1 G85R (53%) displayed nuclear CHOP immunoreactivity compared to those expressing wild-type SOD1. However, when ERp57 was co-expressed with mutant SOD1 G85R , this proportion was significantly decreased, to only 35% of transfected cells showing nuclear CHOP immunoreactivity (**P < 0.01).
We also used siRNA to deplete ERp57 from NSC-34 cells expressing wild-type SOD1, SOD1 A4V or SOD1 G85R followed by immunocytochemistry to examine CHOP activation. Quantification using confocal microscopy ( Fig. 5C ) revealed that the percentage of cells expressing SOD1 A4V (48%) or SOD1
(44%) with nuclear immunoreactivity to CHOP, was significantly increased in Si ERp57 treated cells compared to Si CON treated cells; to SOD1 A4V (65%, **P < 0.01) or SOD1 G85R (56%, **P < 0.01) (Fig. 5D ). Wild-type SOD1-expressing NSC-34 cells with (15%) or without ERp57 siRNA transfection (13%) displayed significantly less nuclear immunoreactivity to CHOP as expected. Hence, together these data demonstrate that ERp57 significantly decreased the proportion of cells with ER stress, detected using two UPR markers, XBP-1 and CHOP. Consistent with these observations, knockdown of ERp57 aggravated ER stress in neuronal cells. These results therefore reveal that ERp57 is protective against ER stress induced by mutant SOD1.
ERp57 rescues ubiquitin proteasome dysfunction induced by mutant SOD1 in neuronal cell lines
Impairment of the proteasome by misfolded mutant SOD1 is linked to the formation of mutant SOD1 inclusions in SOD1-associated ALS, and it induces selective motor neuron death in SOD1 transgenic mice (9) . Hence, the functional activity of the proteasome in cells co-expressing ERp57 with mutant SOD1 was examined using a previously described UPS reporter, 'GFPu', comprised of GFP fused to a degron with a destabilising modification (16 amino acid C-terminal degradation signal, CL-1) that promotes constitutive degradation of GFPu by the UPS (54, 55) . GFPu accumulates when proteasomal function is suppressed, and it has been utilized as a UPS activity reporter in studies of neurodegeneration (56) .
As the EGFP-tagged SOD1 vectors could not be used with GFPu, constructs encoding SOD1 proteins tagged with mCherry were produced. These vectors were co-expressed with GFPu, and either empty vector pcDNA3.1 (as a control) or ERp57-V5. At 72 h post-transfection, cells were imaged using confocal fluorescence microscopy and the percentages of transfected cells (visualized by the presence of mCherry fluorescence) with GFPu expression were quantified (Fig. 6A ). GFP fluorescence was quantified using arbitrary values, and categorized as; <30 (low), 30-70 (medium) and >70 (high), representing the total pixel intensity present in each cell using ImageJ. Hence, in each population, cells were separated into three categories, based on this quantification. In each population, only cells with the greatest GFP pixel fluorescence intensities (>70, categorized as 'high'), were included in the analysis. Very few cells (5%) expressing mCherry alone displayed 'high' GFP fluorescence, as expected, demonstrating that the UPS is functioning normally in these cells. Slightly more cells expressing wild-type SOD1 (14%) displayed 'high' GFP fluorescence, but alone. Densitometric quantitation of ubiquitin levels from the immunoblotting experiments confirmed that there was a significant decrease in the levels of ubiquitin in cells co-expressing ERp57 with mutant SOD1 compared to those expressing mutant SOD1 alone (*P < 0.05). All data are presented as mean 6 SD, n ¼ 3. there was a significant increase in the levels of ubiquitin in Si ERp57 co-transfected cells compared to Si CON. All data are presented as mean 6 SD, n ¼ 3, *P < 0.05 versus respective Si CON co-transfected cells in mutant SOD1 A4V expressing cells and **P < 0.01 versus respective Si CON co-transfected cells in mutant SOD1 G85R expressing cells.
this was not significantly different from mCherry alone. In contrast, significantly more cells expressing mutant SOD1 A4V (45%, ***P < 0.001) or mutant SOD1 G85R (41%, ***P < 0.001) displayed 'high' GFP fluorescence (Fig. 6B ). These data therefore imply that degradation of GFPu was impaired, and hence that the UPS was dysfunctional, in mutant SOD1 (A4V or G85R) expressing cells. However, co-expression of ERp57-V5 with SOD1 A4V resulted in significantly fewer cells (24%, ***P < 0.001) with 'high' GFP 
ERp57 inhibits apoptotic cell death in neuronal cells lines expressing mutant SOD1
Mutant SOD1 triggers apoptosis when expressed in cell culture (26) . Therefore, it was next examined whether ERp57 inhibits apoptosis in cells expressing mutant SOD1 A4V or SOD1 G85R , using several methods. Firstly, the presence of apoptotic nuclei, visualized using Hoechst staining was quantified, as described previously (50) . NSC-34 cells expressing empty vector pEGFP, or wild-type SOD1 or mutant SOD1 A4V with empty vector pcDNA3.1, were counter-stained for Hoechst and examined for fragmented or condensed nuclei at 72 h post-transfection (Fig. 7A ). Similar to previous findings, cells expressing diffuse SOD1 (either wild-type or mutant SOD1
A4V
) that did not form inclusions displayed normal nuclear morphologies, indicating negligible levels of apoptotic cell death (57) . In contrast, 28% of SOD1 A4V expressing cells that bore inclusions contained fragmented nuclei (Fig. 7B) . However, when ERp57 was coexpressed with mutant SOD1
, significantly fewer cells possessed apoptotic nuclei compared to cells expressing SOD1 A4V alone: only 13% displayed condensed or fragmented nuclei (***P < 0.001). Hence, these results imply that ERp57 is protective against apoptosis triggered by mutant SOD1
. Similar findings were obtained when mutant SOD1
G85R was expressed in NSC-34 cells (Fig. 7C ). Fragmented and condensed nuclei were significantly more common in cells expressing SOD1 G85R (21%) than in those expressing empty vector pEGFP or wild-type SOD1, consistent with previous observations. However, co-expression of ERp57 with mutant SOD1 G85R resulted in significantly fewer cells with apoptotic nuclei (15%, ***P < 0.001, Fig. 7D ).
To confirm these findings, we next used siRNA to specifically deplete ERp57 from NSC-34 cells expressing wild-type SOD1, SOD1 A4V or SOD1
G85R
. The formation of apoptotic nuclei was examined using Hoechst staining (Fig. 7E) . Wild-type SOD1 expressing NSC-34 cells with (3%) or without (4%) ERp57 siRNA transfection (Fig. 7F) , bore few apoptotic nuclei. The percentage of cells with apoptotic nuclei in Si ERp57-treated populations expressing SOD1 A4V (27%, ***P < 0.001) or SOD1 G85R (21%, *p < 0.05), was significantly increased compared to control cells treated with Si CON, where apoptosis was detected in only 15% of SOD1 A4V or 13% of SOD1 G85R populations. Hence these results imply that
ERp57 is protective against apoptosis induced by mutant SOD1.
To further confirm these findings, two other markers of apoptosis were examined. Firstly, immunocytochemistry using antibodies specific for the activated, cleaved form of caspase-3, with counter-staining for Hoechst, (Fig. 7G) , significantly fewer cells (18%, ***P < 0.001, Fig. 7H ) demonstrated caspase-3 activation.
Similarly, we next quantified induction of apoptosis using annexin V/propidium iodide (PI) staining by flow cytometry (58) after 72 h transfection with mutant SOD1
A4V
. In Neuro2a populations, we observed significantly less apoptosis in cells coexpressing SOD1 A4V and ERp57 compared to cells co-expressing SOD1 A4V and pcDNA3.1 (*P < 0.05) (Fig. 8A) . As observed in the bottom right quadrant of the flow cytometry density plots, which represent early apoptotic events (Annexin V-positive, Sytox Blue-negative population), cells expressing SOD1 A4V with empty vector showed fewer events compared to cells coexpressing SOD1 A4V with ERp57 (dark blue compared to light blue). Hence, these results confirm that ERp57 is protective against apoptosis triggered by mutant SOD1 A4V .
ERp57 inhibits apoptotic cell death in primary neurons expressing mutant SOD1
To confirm the above observations obtained in cell lines, primary mouse cortical neurons were next co-transfected with constructs encoding SOD1-EGFP and ERp57-V5 as above (Fig. 9A) . Primary neurons expressing pEGFP alone (7%) or wildtype SOD1 (4%) bore few apoptotic nuclei, as expected. Similar to previous observations (51), this contrasted with 64% (**P < 0.01) of neurons co-expressing mutant SOD1 A4V with empty vector (pcDNA3.1) that displayed apoptotic nuclei. However, this proportion was significantly decreased to 24% (*P < 0.05) of cells when ERp57 was co-expressed with (Fig. 9B) , thus confirming that ERp57 is protective against apoptosis.
Endogenous ERp57 co-localizes with phospho-TDP-43 inclusions in sporadic ALS patients
Next, we examined whether ERp57 associates with pathological forms of TDP-43 (phosphorylated TDP-43 inclusions), which are present in almost all ALS cases, including human sporadic tissues. We performed double immunohistochemistry of postmortem cervical spinal cord sections of three sALS patients and two control individuals, using antibodies against ERp57 and phospho-TDP-43 (Fig. 10A) . ERp57 was expressed diffusely in neurons of control individuals (row 1), whereas it co-localized with phospho-TDP-43-positive inclusions in those of sALS patients (row 2). This was further confirmed by observing the orthogonal section of the Z stack image (Fig. 10B) . Quantification of the degree of co-localization was also performed using Mander's coefficient, revealing significant overlap between phospho-TDP-43-positive inclusions and endogenous ERp57 (30%, ***P<.001, Fig. 10C ). These data reveal that ERp57 associates with pathological forms of TDP-43, implying that it has a protective role against protein misfolding in human sporadic ALS.
Discussion
Several proteins are genetically and pathologically linked to ALS, notably SOD1 and TDP-43, which together account for approximately 25% of fALS cases (59) . Importantly, TDP-43 pathology is recognized as the signature pathological lesion of sALS and most forms of fALS, because it is present in almost all ALS cases (13, 60, 61) . Despite the diverse functions of the proteins associated with ALS, each form has a remarkably similar disease course and pathology. Disturbances to proteostasis are increasingly implicated in ALS, and the finding that ERp57 is protective against multiple aspects of proteostasis, including ER stress, inclusion formation and proteasomal disturbances, as well as cell death, indicates a functional role for ERp57 in ALS pathology.
Proteins of the PDI family are now emerging as possible therapeutic targets and biomarkers in neurodegenerative diseases associated with protein misfolding and ER stress. We previously demonstrated that the prototype of this family, PDIA1, was protective against inclusion formation, ER stress and apoptosis, in cells expressing mutant SOD1 (26) . In the current study, we examined whether the PDI family member ERp57 is also protective in vitro in ALS, to provide insights into the specificity of this activity and thus the requirements for protection. We found that ERp57 was protective against mutant SOD1-induced inclusion formation, ER stress, UPS dysfunction and apoptosis in motor neuronal cell lines. These findings were validated by siRNA studies to knockdown ERp57. We also observed that over-expression of ERp57 is protective against mutant SOD1-induced inclusion formation and apoptosis in mouse primary cortical neurons, thus confirming that ERp57 is protective when expressed in neurons. Hence, these data demonstrate that ERp57 has broad protective activity in vitro, implying an important protective role for ERp57, the closest known homologue of PDIA1, against misfolded proteins associated with ALS.
ERp57 also co-localized with phospho-TDP-43-positive inclusions in sporadic ALS patient motor neurons, suggesting that it interacts with pathological forms of TDP-43 as a cellular defence mechanism. However, it has not yet been examined whether SOD1 and TDP-43 are potential substrates of PDI family members. ERp57 primarily interacts with glycosylated substrates, but both PDIA1 and ERp57 have broader substrate specificity compared to other PDI family members (33, 62) . One study identified endogenous protein substrates of PDI family members, including PDIA1, ERp72, ERp57, ERp18, ERp46 and PDIA6, and reported that the different PDI family members have distinct substrate specificities (62) . It is therefore possible that different PDI family members prevent misfolding of specific substrates and that each misfolded protein engages specific family members. Alternatively, PDI family members may interact with their substrates in a cell-type specific manner. Also, since PDIA1 becomes non-functional by aberrant S-nitrosylation in ALS (26), it is possible that PDI family members may compensate for each other's function (63, 64) . It remains unclear however, whether the normal protective activity of ERp57 is inhibited by S-nitrosylated in ALS. Hence, further investigation into the mechanism of the protective action of ERp57 are warranted, including whether ERp57 is aberrantly modified by Snitrosylation.
Similar to PDIA1, ERp57 has the dual property of being a chaperone and oxidoreductase (32) . Hence, it inhibits the aggregation of protein substrates that do not contain disulphide bonds, and it also isomerizes disulphide bonds within proteins to form the native conformation. The CXXC active site motif within the catalytic 'a' domains of PDI family members is responsible for the disulphide interchange activity (29) , and hence the formation of disulphide bonds. However, it remains unclear which property of ERp57 is protective in cells expressing mutant SOD1. Several studies have demonstrated that mutations in SOD1 lead to the formation of aberrant intermolecular disulphide bonds, inducing SOD1 aggregation and toxicity (15) . Together, these findings imply that the disulphide interchange activity of PDI family members is important against protein misfolding, but further studies need to be performed to examine this specifically.
It also remains to be determined in which subcellular compartment ERp57 interacts with mutant SOD1 in preventing protein misfolding, if indeed they directly interact. Although primarily ER-resident, ERp57 has also been detected in the nucleus, mitochondria and cytosol (65) . Previous studies have speculated that mutant SOD1 is present in the ER (66) , although this appears unlikely based on results from our and other laboratories (67, 68) . However, PDI family members undergo significant changes in conformation and cellular localization in response to cellular conditions, and ER stress can trigger redistribution of ERp57 to the cytoplasm (69) . Hence, together these findings point to the cytoplasm as the active cellular compartment for ERp57, although further studies are necessary to confirm this. NSC-34 cells were co-transfected with wild-type SOD1 (SOD1-WT) or SOD1 G85R (SOD1-G85R) (green) and ERp57 (red), and examined by confocal microscopy at 72 h posttransfection. Nuclei are shown by Hoechst stain (blue). Arrow represents condensed or fragmented nuclei, indicating that apoptosis is underway. Few cells expressing PDI family members are abundant proteins that are responsible for disulphide bond formation (62, 70) . Hence, given their importance in normal cellular function, dysfunction of PDI family members could lead to protein misfolding and possibly, diseases associated with this. Recent work (43) demonstrated that mutations in PDIA1 and PDIA3 induce disruption of motor neuron connectivity in zebrafish and loss of neuromuscular synapses in mice, suggesting that the PDIA1 and ERp57 mutants may contribute to disease by both gain and loss-of-function mechanisms. They also highlight the possibility that PDI family members have important roles in vivo in neurons. However, PDIA1 is responsible for oxidizing other PDI family members, including ERp57, via the endoplasmic reticulum oxidase 1a (ERo1a) pathway, thus accelerating the formation of disulphide bonds by these family members (71). Hence, it is possible that loss of function of PDIA1 would affect the normal cellular functions of ERp57 in ALS. Therefore, replenishing ERp57 could be another way of protecting motor neurons against cellular stressors in ALS.
Conclusions
In summary, this study demonstrates that a novel PDI family member, ERp57, is protective against protein misfolding, UPS dysfunction, ER stress and toxicity, in cells expressing mutant SOD1. Since the death of motor neurons is central to ALS, the protective effect of ERp57 on neuronal apoptosis implies that it has potential as a novel therapeutic target. Therefore, this study sheds new light on possible ways to develop novel therapeutics with protective activity against protein misfolding, one of the major pathological hallmarks in ALS and other neurodegenerative disorders. Furthermore, the results of this study imply that as well as PDIA1, other members of the PDI family may have specific roles in protein misfolding and protection against ALS pathology. Hence, targeting the specific modes of action of individual PDI family members may represent a novel approach for the development of pharmacological agents based on PDI functions.
Materials and Methods
Cell lines
Mouse motor neuron-like NSC-34 cells were kindly provided by Professor Neil Cashman, University of Toronto. Mouse neuroblastoma Neuro2a cell lines (ATCC cell line CCL-131) were maintained in Dulbecco's modified eagle medium (DMEM) with 10% fetal calf serum (FCS).
Constructs
Expression constructs for ERp57-V5 in pcDNA3.1(þ) were a generous gift from Dr Neil Bulleid, University of Glasgow, UK (62) . The SOD1-EGFP-N1 constructs were as described earlier (72) and the GFPu construct was kindly provided by Dr Justin Yerbury, Illawarra Health and Medical Research Institute, University of Wollongong. The SOD1-mCherry constructs were generated by replacing the pEGFP sequence in the SOD1-EGFP-N1 constructs with the mCherry fluorescent protein sequence from the pmCherry-N1 vector, by digestion with SalI. The sequence was confirmed using DNA sequencing.
Cell culture and transfection
NSC-34 cells and Neuro2a cells were maintained in DMEM with 10% FCS, and incubated at 37 C with 5% CO 2 . Transfections were performed using Lipofectamine TM 2000 (Invitrogen) according to the manufacturer's protocol. Cells were co-transfected with SOD1 (EGFP/mCherry) and ERp57-V5 constructs and observed 72 h post-transfection using fluorescence microscopy.
Immunoblotting
Cell lysates were collected in cold TN buffer (50 mM Tris-HCl pH 7.5 and 150 mM NaCl, pH 7.6) with 1% Triton-X 100, protease inhibitors (pi, 1:1000), phosphatase inhibitors (ppi, 1:100) and Phenylmethanesulfonyl fluoride [PMSF, Sigma #P7626-250MG (1: 500)], then incubated on ice for 15 min and stored at À20 C overnight. Samples were sonicated for 10Â 1 00 bursts and centrifuged at 100,000g at 4 C for 30 min to obtain the SDS-soluble fraction. The insoluble pellet was washed with TN buffer containing Triton-x 100 and pi/ppi/PMSF, sonicated and centrifuged again as above. The supernatant was discarded, and the pellet was resolubilized with 50 ul TN buffer with 2% SDS, then sonicated and centrifuged again at 22 C. Protein concentrations of cell lysates were determined using the BCA protein assay Immunofluorescence and microscopy NSC-34 cells were fixed in 4% paraformaldehyde, permeabilized with 0.1% Triton-X in phosphate buffered saline (PBS), blocked with 3% BSA in PBS, followed by incubation with mouse anti-CHOP (1:50, Santa Cruz), rabbit anti-XBP-1 (1:20, Santa Cruz), mouse anti-V5 (1:250, Abcam) anti-rabbit active cleaved-caspase-3 (1:20, Cell Signalling) antibodies in PBS at 4 C overnight.
The secondary antibodies, AlexaFluor 568-conjugated rabbit anti-mouse IgG (1:250) or goat-anti-rabbit IgG AlexaFluor 568, were added for 1 h and incubated in the dark at room temperature. After washing with PBS, staining of nuclei was performed using Hoechst stain 33342 (Invitrogen, nuclei), FITC (GFP fluorescence) and TRITC (red fluorescence) filters were used for viewing the cells and the images were taken using a Zeiss confocal Axioimager microscope or LSM 880 Zeiss confocal microscope.
In dual-channel imaging, photomultiplier sensitivities and offsets were set to a level at which bleed-through effects from one channel to another were negligible.
Image analysis
For Figure 6C the GFP fluorescence was quantified using ImageJ, by calculating corrected total cell fluorescence [CTCF ¼ Integrated density À (Area of selected cells Â Mean fluorescence of background readings)] (73). Twenty cells were scored in each experiment and all experiments were performed in triplicate. For Figure 10C , plugins were used in ImageJ, and the measuring areas were selected above a threshold against background staining. After analysis, Mander's coefficient (74) in the range from 0 to 1.0 (representing 0-100% overlapping pixels) was calculated to determine the degree of overlap between images.
Small interfering RNA 
Cortical neuronal culture
Primary neurons were harvested from the cortex of C57BL/6 mouse embryos at embryonic day 16-18. The procedure for culture of primary neurons was as described previously (75, 76) . Briefly, cortical tissue was dissected under sterile conditions in Hanks' Balanced Salt solution (HBSS, Gibco) and digested in 10 units/ml papain (Sigma) in 2 mg/ml L-cysteine (Sigma) and 0.5 mM EDTA, pH 8 (Sigma) in DMEM, for 15 min at 37 C. Cells were subsequently triturated using pipette tips so they were dissociated, then resuspended in platting medium (DMEM, 10% FBS, 100 mg/ml penicillin-streptavidin) and seeded for 1 h on 15 mm glass coverslips, previously coated with 0.1 mg/ml poly-D-lysine overnight. Cells were then incubated in neuronal medium [Neurobasal medium supplemented with 2% B27, supplement (Gibco), 1% Glutamax (Gibco) and 100 mg/ml penicillin-streptavidin] at 37 C and 5% CO 2 .
Primary neuron transfection 
Primary neuron immunocytochemistry
Cortical neurons transfected with SOD1 constructs for 72 h were washed in PBS and fixed in 4% paraformaldehyde in PBS for 10 min. After three washes in PBS, cells were permeabilized in 0.1% Triton X-100 in PBS for 5 min and the non-specific background staining was blocked using 3% (wt/v) BSA in PBS for 45 min at room temperature with gentle rocking. Cells were then incubated overnight at 4 C with rabbit anti-V5 antibody (Sigma V8137-2MG) diluted in 1% (wt/v) BSA in PBS. After rinsing, cells were incubated for 1 h at room temperature with anti-rabbit secondary antibodies coupled to AlexaFluor 594 (Molecular Probes) diluted 1:250 in PBS. Cells were then washed as above and treated with 0.5 mg/ml Hoechst 33342 reagent (Sigma). After three washes in PBS, coverslips were mounted onto slides in fluorescent mounting medium (Dako). Cells were then examined and photographed with 40x/na ¼ 1.3 or 100x/na ¼ 1.46 objectives on a Zeiss LSM 880 inverted confocal laser-scanning microscope, equipped with a LSM-TPMT camera (Zeiss).
Apoptosis analysis by flow cytometry annexin V assay
Neuro2A cells were plated onto 12-well plates and cotransfected with either EGFP-tagged SOD1 A4V and pcDNA3.1, or SOD1 A4V and ERp57-V5-pcDNA3.1. Cells were collected by treatment with trypsin 72 h post-transfection, and resuspended in 100 ml Annexin V binding buffer to achieve a final concentration of 1 Â 10 6 cells/ml. Cells were then simultaneously labelled with presented as a fold change compared to cells transfected with SOD1 A4V and pcDNA3.1.
ERp57 and TDP-43 immunohistochemistry
Paraffin-embedded post-mortem human cervical spinal cord sections (5 mm) from non-neurological controls and sporadic ALS patients were obtained from the New South Wales (NSW) Brain Bank Network (Table 1 ). The tissue sections were preheated at 60˚C for 30 min, paraffin removed by washing with xylene twice, followed by washing with 100% ethanol, 95% ethanol and then 70% ethanol. The sections were then washed twice with distilled water. scanning microscope. Quantification was performed from 9 neurons in control individuals and from 24 neurons in ALS patients.
Statistics
At least 100 co-expressing cells were examined in each experiment and the data was represented as mean 6 SD. Each experiment was performed three times with the experimenter blinded. Statistical analyses were made using ANOVA followed by Tukey's post-hoc test (GraphPad Prism 5, San Diego, CA). Pvalues of 0.05 or less were considered significant: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. 
